Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma
Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas
Sponsor: National Cancer Institute (NCI)
Listed as NCT00010049, this PHASE1/PHASE2 trial focuses on Brain and Central Nervous System Tumors and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 6 times since 2001, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jul 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Completed PHASE1_PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
First recorded
Feb 2001
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
For direct contact, visit the study record on ClinicalTrials.gov .